Vectron T500 (Broflanilide 50WP) for IRS in Tanzania Tanzania
WHO Phase III Evaluation of Vectron T500 (Broflanilide 50WP) for IRS in Tanzania
2 other identifiers
interventional
12,500
2 countries
2
Brief Summary
Malaria is a major public health problem in Africa. An important way to control the disease is by Indoor Residual Spraying of insecticide in houses. Insecticide resistance has become a major problem. This trial will evaluate a novel insecticide against those insecticide resistant mosquito vectors in Tanzania E Africa.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Oct 2020
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2020
CompletedFirst Submitted
Initial submission to the registry
November 26, 2021
CompletedFirst Posted
Study publicly available on registry
December 9, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedDecember 9, 2021
November 1, 2021
1.7 years
November 26, 2021
November 26, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Vector density
Reduction in vector population density
12-15 months
Sporozoite rate
Reduction in sporozoite rate
12-15 months
Entomological inoculation rate EIR
Reduction in EIR
12-15 months
Study Arms (2)
Intervention IRS
ACTIVE COMPARATORIntervention IRS insecticide will be sprayed on the walls and ceilings of 8 clusters
Control IRS
ACTIVE COMPARATORWHO approved IRS insecticide will be sprayed on the walls and ceilings of 8 clusters
Interventions
public health insecticide
Eligibility Criteria
You may qualify if:
- All households who consent to IRS malaria control
You may not qualify if:
- none
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
National Institute of Medical Research
Muheza, Tanzania
London School of Hygiene & Tropical Medicine
London, WC1E 7HT, United Kingdom
Related Publications (2)
Mbewe NJ, Tungu PK, Messenger LA, Bradley J, Mangesho PE, Shirima B, Moshi O, Shayo MF, Seif M, Portwood NM, Snetselaar J, Azizi S, Magogo F, Mabenga P, Sudi W, Mlay G, Kirby MJ, Mosha FW, Kisinza W, Matowo J, Small G, Rowland MW. A noninferiority cluster randomised evaluation of a broflanilide indoor residual spraying insecticide, VECTRON T500, for malaria vector control in Tanzania. Sci Rep. 2025 Apr 29;15(1):15013. doi: 10.1038/s41598-025-99809-9.
PMID: 40301570DERIVEDTungu PK, Rowland MW, Messenger LA, Small GJ, Bradley J, Snetselaar J, Kirby MJ, Mbewe NJ. Large-scale (Phase III) evaluation of broflanilide 50WP (VECTRON T500) for indoor residual spraying for malaria vector control in Northeast Tanzania: study protocol for a two-arm, non-inferiority, cluster-randomised community trial. BMC Infect Dis. 2022 Feb 21;22(1):171. doi: 10.1186/s12879-022-07138-3.
PMID: 35189830DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, CARE PROVIDER
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 26, 2021
First Posted
December 9, 2021
Study Start
October 1, 2020
Primary Completion
June 30, 2022
Study Completion
December 31, 2022
Last Updated
December 9, 2021
Record last verified: 2021-11
Data Sharing
- IPD Sharing
- Will not share